A regimen of Exelixis, Inc.’ Cabometyx and Roche Holding AG’s Tecentriq has missed the mark in the Phase III CONTACT-03 trial in advanced renal cancer patients, but is shrugging off the failure in light of more commercially important pivotal cancer readouts for the product expected later this year.
CONTACT-03 enrolled 522 people with locally advanced or metastatic clear cell or non-clear cell renal cell carcinoma (RCC) whose disease...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)